Home » FDA Grants Incyte’s Jakafi Breakthrough Therapy Designation
FDA Grants Incyte’s Jakafi Breakthrough Therapy Designation
Incyte’s Jakafi has secured breakthrough therapy designation for treatment of patients with acute graft-versus-host disease, the Wilmington, Del.-based company announced last week.
Jakafi is indicated to treat people with polycythemia vera who aren’t responsive to hydroxyurea, as well as people with intermediate or high-risk myelofibrosis.
Currently, there are no approved treatments for patients with acute GVHD.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May